In: NEOPLASMA, vol. 52, no. 5
D. Feltl - E. Závadová - M. Pála - P. Hozák
Detaily:
Rok, strany: 2005, 393 - 397
O článku:
Between 2001 and 2002, 29 patients with advanced inoperable
squamous head and neck cancer treated with radiotherapy
with or without simultaneous chemotherapy were evaluated for their
plasma TGF-β1 levels prior to the treatment, in the
middle of the radiotherapy course and at the end of the treatment.
Patients were assessed for treatment response and late
morbidity. Predictive value of TGF-β1 level on either of the
assessed parameters was tested.
From 29 eligible patients (pts), 18 achieved complete response, 8
partial response and three pts progressed primarily. After
a median follow-up of 16 months we recorded 16 cases of grade >1
late morbidity. We found that posttreatment elevated
plasma TGF-β1 level predicts late morbidity grade >1 (p=0.05)
rather than pretreatment level (p=0.062). Neither pretreatment
nor posttreatment plasma TGF-β1 level has a predictive value to
the treatment response (CR vs. no CR, p=0.125 and
0.252, respectively).
The posttreatment plasma TGF-beta 1 level can predict late
morbidity grade >1 in advanced head and neck cancer treated
with radio(chemo)therapy. This could make a basis for dose
escalation in selected patients.
Ako citovať:
ISO 690:
Feltl, D., Závadová, E., Pála, M., Hozák, P. 2005. Posttreatment plasma transforming growth factor beta 1 (TGF-beta1)
level
predicts for late morbidity in patients with advanced head and
neck cancer. In NEOPLASMA, vol. 52, no.5, pp. 393-397. 0028-2685.
APA:
Feltl, D., Závadová, E., Pála, M., Hozák, P. (2005). Posttreatment plasma transforming growth factor beta 1 (TGF-beta1)
level
predicts for late morbidity in patients with advanced head and
neck cancer. NEOPLASMA, 52(5), 393-397. 0028-2685.